Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2003-12-08
2011-10-11
Yu, Misook (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C530S388220, C530S388800, C530S391700, C424S009100, C424S133100, C424S141100, C424S143100, C424S155100, C424S178100, C424S181100
Reexamination Certificate
active
08034904
ABSTRACT:
Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.
REFERENCES:
patent: 5530101 (1996-06-01), Queen et al.
patent: 5844093 (1998-12-01), Kettleborough et al.
patent: 6309636 (2001-10-01), do Couto et al.
patent: 6610500 (2003-08-01), Saragovi et al.
patent: 6875741 (2005-04-01), Pillutla et al.
patent: 7538195 (2009-05-01), Singh et al.
patent: 2003/0018191 (2003-01-01), Tinkl et al.
patent: 2003/0099655 (2003-05-01), Watkins et al.
patent: 2003/0165502 (2003-09-01), Fujita-Yamaguchi
patent: 2003/0236190 (2003-12-01), Pillutla et al.
patent: 2004/0023887 (2004-02-01), Pillutla et al.
patent: 2004/0086503 (2004-05-01), Cohen et al.
patent: 2005/0084906 (2005-04-01), Goetsch et al.
patent: 92/08471 (1992-05-01), None
patent: WO 00/34780 (2000-06-01), None
patent: WO 02/053596 (2002-07-01), None
patent: WO 03/059951 (2003-07-01), None
patent: WO 03/100008 (2003-12-01), None
patent: WO 03/106621 (2003-12-01), None
patent: WO 2004/071529 (2004-08-01), None
patent: WO 2004/083248 (2004-09-01), None
Tan et al., Cancer Research 62:1083-1086, Feb. 15, 2002.
Rohlik et al., Biochemical and Biophysical Research Communications 149:276-281, Nov. 30, 1987.
Teicher et al., Clinical Cancer Research 5(2638-2645, Sep. 1999.
Holm et al. (Mol. Immunol. Feb. 2007; 44 (6): 1075-1084).
Winkler et al. (J. Immunol. Oct. 15, 2000; 165 (8): 4505-4514).
Casset et al. (Biochem. Biophys. Res. Commun. Jul. 18, 2003; 307 (1): 198-205).
MacCallum et al. (J. Mol. Biol. Oct. 11, 1996; 262 (5): 732-745).
Mariuzza et al. (Annu. Rev. Biophys. Biophys. Chem. 1987; 16: 139-159).
Gussow et al. (Methods in Enzymology. 1991; 203: 99-121).
Giusti et al. (Proc. Natl. Acad. Sci. USA. May 1987; 84 (9): 2926-2930).
Chien et al. (Proc. Natl. Acad. Sci. USA. Jul. 1989; 86 (14): 5532-5536).
Caldas et al. (Mol. Immunol. May 2003; 39 (15): 941-952).
Vajdos et al. (J. Mol. Biol. Jul. 5, 2002; 320 (2): 415-428).
Lam et al (HKMJ, 5(2):180-186, 1999).
Li et al.,Cancer Immunol. lmmunother. 49:243-252 (2000).
Maloney et al,Cancer Research, 63(16):5073-5083 (2003).
Grant et al,J. Clin. Endocrin. Metabol., 83:3252-3257 (1998).
Steele-Perkins and Roth,Biochem. Biophys. Res. Comm. 171(3):1244-1251 (1990).
Harlow and Lane, eds. Using Antibodies, A Laboratory Manual, pp. 81-97, 126-127, 166-169, Cold Spring Harbor Press 1999.
Kato et al. ,J. Biot. Chem. 268:2655-2661 (1993).
Fundamental Immunology, William E. Paul, M.D. ed., 3d ed., p. 242, 1993.
Rudikoff et al.,Proc. Natl. Acad. Sci USA, 79:1979-1983 (1982).
Zia et al.,J. Cellular Biochem Suppl. 24:269-275 (1996).
Roguska et al.,Proc. Natl. Acad. Aci USA, 91:969-973 (1994).
Surmacz, “Growth Factor Receptors as Therapeutic Targets: Strategies to Inhibit the Insulin-like Growth Factor I Receiptor”,Oncogene, Nature Publishing Group, GB Basingstoke, Hants; 22(42):6589-6597 (2003).
Dagdigian Nancy E.
Singh Rajeeva
Tavares Daniel J.
Duffy Brad
Immunogen Inc.
Sughrue & Mion, PLLC
Yu Misook
LandOfFree
Anti-IGF-I receptor antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-IGF-I receptor antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-IGF-I receptor antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4278548